**Core Concept**
Phase 3 of the drug development process refers to the clinical efficacy and safety evaluation of a new drug in a larger population of patients. This phase involves randomized controlled trials (RCTs) to assess the drug's efficacy, safety, and tolerability in a diverse group of patients.

**Why the Correct Answer is Right**
The primary objective of Phase 3 trials is to confirm the efficacy and safety of a drug in a larger patient population, compared to the smaller number of patients in Phase 2 trials. The results of Phase 3 trials are used to support the drug's approval by regulatory agencies, such as the FDA. These trials typically involve 100-3000 patients and are designed to detect small but clinically significant differences between the treatment and control groups.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because Phase 1 trials are primarily focused on assessing the drug's safety and pharmacokinetics in a small number of healthy volunteers.
**Option B:** This option is incorrect because Phase 2 trials are focused on assessing the drug's efficacy and safety in a larger number of patients with the target disease or condition.
**Option C:** This option is incorrect because Phase 4 trials are post-marketing surveillance studies that are conducted after the drug has been approved by regulatory agencies.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that Phase 3 trials are a critical step in the drug development process, and the results of these trials can significantly impact the approval and marketing of a new drug.

**Correct Answer: C. Phase 4 trials are post-marketing surveillance studies that are conducted after the drug has been approved by regulatory agencies.